Lenox Wealth Management Inc. raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 31.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 92,392 shares of the company’s stock after acquiring an additional 21,944 shares during the period. Novo Nordisk A/S comprises about 1.5% of Lenox Wealth Management Inc.’s investment portfolio, making the stock its 8th largest holding. Lenox Wealth Management Inc.’s holdings in Novo Nordisk A/S were worth $4,448,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Private Advisor Group LLC boosted its position in shares of Novo Nordisk A/S by 20.0% during the third quarter. Private Advisor Group LLC now owns 13,959 shares of the company’s stock worth $683,000 after buying an additional 2,330 shares during the period. BB&T Investment Services Inc. boosted its position in shares of Novo Nordisk A/S by 48.8% during the third quarter. BB&T Investment Services Inc. now owns 17,947 shares of the company’s stock worth $865,000 after buying an additional 5,885 shares during the period. Pinnacle Associates Ltd. boosted its position in shares of Novo Nordisk A/S by 5.5% during the third quarter. Pinnacle Associates Ltd. now owns 90,503 shares of the company’s stock worth $4,358,000 after buying an additional 4,716 shares during the period. Woodmont Investment Counsel LLC bought a new stake in Novo Nordisk A/S during the third quarter worth about $1,023,000. Finally, JPMorgan Chase & Co. raised its holdings in Novo Nordisk A/S by 14.7% during the third quarter. JPMorgan Chase & Co. now owns 679,323 shares of the company’s stock worth $32,654,000 after acquiring an additional 87,175 shares in the last quarter. 6.18% of the stock is owned by hedge funds and other institutional investors.
Several research firms recently issued reports on NVO. Zacks Investment Research lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Bank of America upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Wednesday. BNP Paribas lowered Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Monday, September 25th. BidaskClub upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Finally, Morgan Stanley upgraded Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a report on Friday, December 1st. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $55.00.
Shares of Novo Nordisk A/S (NYSE NVO) traded down $0.29 during midday trading on Thursday, hitting $51.78. The stock had a trading volume of 606,717 shares, compared to its average volume of 2,098,421. The company has a market capitalization of $129,285.00, a price-to-earnings ratio of 22.14, a P/E/G ratio of 3.01 and a beta of 0.63. Novo Nordisk A/S has a one year low of $32.83 and a one year high of $52.45.
In other news, insider Eric S. Sprott bought 50,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were bought at an average price of $8.34 per share, for a total transaction of $417,000.00. 0.07% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.thestockobserver.com/2017/12/07/novo-nordisk-a-s-nvo-is-lenox-wealth-management-inc-s-8th-largest-position.html.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.